Intrinsic value of DexCom - DXCM

Previous Close

$73.06

  Intrinsic Value

$0.82

stock screener

  Rating & Target

str. sell

-99%

  Value-price divergence*

-77%

Previous close

$73.06

 
Intrinsic value

$0.82

 
Up/down potential

-99%

 
Rating

str. sell

 
Value-price divergence*

-77%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of DXCM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 6.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  42.54
  22.40
  20.66
  19.09
  17.68
  16.42
  15.27
  14.25
  13.32
  12.49
  11.74
  11.07
  10.46
  9.91
  9.42
  8.98
  8.58
  8.22
  7.90
  7.61
  7.35
  7.12
  6.90
  6.71
  6.54
  6.39
  6.25
  6.12
  6.01
  5.91
  5.82
Revenue, $m
  573
  701
  846
  1,008
  1,186
  1,381
  1,592
  1,818
  2,061
  2,318
  2,590
  2,877
  3,178
  3,493
  3,822
  4,165
  4,523
  4,895
  5,282
  5,684
  6,101
  6,535
  6,987
  7,456
  7,943
  8,451
  8,979
  9,529
  10,102
  10,699
  11,321
Variable operating expenses, $m
 
  729
  880
  1,047
  1,232
  1,434
  1,653
  1,889
  2,140
  2,407
  2,690
  2,986
  3,299
  3,626
  3,968
  4,324
  4,695
  5,081
  5,483
  5,900
  6,334
  6,784
  7,253
  7,740
  8,246
  8,773
  9,321
  9,892
  10,486
  11,106
  11,753
Fixed operating expenses, $m
 
  43
  44
  45
  46
  48
  49
  50
  51
  52
  54
  55
  56
  58
  59
  61
  62
  64
  66
  67
  69
  71
  72
  74
  76
  78
  80
  82
  84
  86
  88
Total operating expenses, $m
  637
  772
  924
  1,092
  1,278
  1,482
  1,702
  1,939
  2,191
  2,459
  2,744
  3,041
  3,355
  3,684
  4,027
  4,385
  4,757
  5,145
  5,549
  5,967
  6,403
  6,855
  7,325
  7,814
  8,322
  8,851
  9,401
  9,974
  10,570
  11,192
  11,841
Operating income, $m
  -64
  -71
  -77
  -85
  -93
  -101
  -110
  -120
  -131
  -142
  -154
  -165
  -177
  -191
  -205
  -219
  -235
  -250
  -267
  -284
  -301
  -319
  -338
  -358
  -378
  -400
  -422
  -445
  -469
  -493
  -519
EBITDA, $m
  -49
  -60
  -64
  -69
  -74
  -80
  -86
  -93
  -100
  -107
  -115
  -123
  -131
  -140
  -149
  -159
  -169
  -179
  -190
  -201
  -212
  -224
  -236
  -249
  -262
  -276
  -291
  -306
  -321
  -337
  -354
Interest expense (income), $m
  0
  0
  1
  2
  3
  4
  6
  7
  9
  11
  13
  15
  17
  19
  21
  24
  26
  29
  31
  34
  37
  40
  43
  47
  50
  54
  57
  61
  65
  69
  74
Earnings before tax, $m
  -65
  -71
  -78
  -87
  -96
  -106
  -116
  -128
  -140
  -153
  -166
  -179
  -194
  -210
  -226
  -243
  -261
  -279
  -298
  -318
  -338
  -360
  -382
  -405
  -429
  -453
  -479
  -506
  -534
  -563
  -593
Tax expense, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -66
  -71
  -78
  -87
  -96
  -106
  -116
  -128
  -140
  -153
  -166
  -179
  -194
  -210
  -226
  -243
  -261
  -279
  -298
  -318
  -338
  -360
  -382
  -405
  -429
  -453
  -479
  -506
  -534
  -563
  -593

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  124
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  403
  341
  412
  491
  577
  672
  775
  885
  1,003
  1,129
  1,261
  1,401
  1,547
  1,701
  1,861
  2,028
  2,202
  2,383
  2,571
  2,767
  2,970
  3,182
  3,401
  3,630
  3,867
  4,114
  4,371
  4,639
  4,918
  5,209
  5,512
Adjusted assets (=assets-cash), $m
  279
  341
  412
  491
  577
  672
  775
  885
  1,003
  1,129
  1,261
  1,401
  1,547
  1,701
  1,861
  2,028
  2,202
  2,383
  2,571
  2,767
  2,970
  3,182
  3,401
  3,630
  3,867
  4,114
  4,371
  4,639
  4,918
  5,209
  5,512
Revenue / Adjusted assets
  2.054
  2.056
  2.053
  2.053
  2.055
  2.055
  2.054
  2.054
  2.055
  2.053
  2.054
  2.054
  2.054
  2.053
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
Average production assets, $m
  84
  102
  124
  147
  173
  202
  232
  265
  301
  338
  378
  420
  464
  510
  558
  608
  660
  715
  771
  830
  891
  954
  1,020
  1,089
  1,160
  1,234
  1,311
  1,391
  1,475
  1,562
  1,653
Working capital, $m
  178
  66
  80
  95
  111
  130
  150
  171
  194
  218
  243
  270
  299
  328
  359
  392
  425
  460
  496
  534
  574
  614
  657
  701
  747
  794
  844
  896
  950
  1,006
  1,064
Total debt, $m
  0
  27
  57
  91
  128
  168
  212
  259
  309
  363
  419
  479
  542
  607
  676
  747
  821
  899
  979
  1,063
  1,149
  1,240
  1,333
  1,431
  1,532
  1,638
  1,748
  1,862
  1,981
  2,105
  2,235
Total liabilities, $m
  119
  146
  176
  210
  247
  287
  331
  378
  428
  482
  538
  598
  661
  726
  795
  866
  940
  1,018
  1,098
  1,182
  1,268
  1,359
  1,452
  1,550
  1,651
  1,757
  1,867
  1,981
  2,100
  2,224
  2,354
Total equity, $m
  284
  196
  236
  281
  331
  385
  444
  507
  575
  647
  723
  803
  887
  974
  1,066
  1,162
  1,262
  1,365
  1,473
  1,586
  1,702
  1,823
  1,949
  2,080
  2,216
  2,358
  2,505
  2,658
  2,818
  2,985
  3,158
Total liabilities and equity, $m
  403
  342
  412
  491
  578
  672
  775
  885
  1,003
  1,129
  1,261
  1,401
  1,548
  1,700
  1,861
  2,028
  2,202
  2,383
  2,571
  2,768
  2,970
  3,182
  3,401
  3,630
  3,867
  4,115
  4,372
  4,639
  4,918
  5,209
  5,512
Debt-to-equity ratio
  0.000
  0.140
  0.240
  0.320
  0.390
  0.440
  0.480
  0.510
  0.540
  0.560
  0.580
  0.600
  0.610
  0.620
  0.630
  0.640
  0.650
  0.660
  0.660
  0.670
  0.680
  0.680
  0.680
  0.690
  0.690
  0.690
  0.700
  0.700
  0.700
  0.710
  0.710
Adjusted equity ratio
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -66
  -71
  -78
  -87
  -96
  -106
  -116
  -128
  -140
  -153
  -166
  -179
  -194
  -210
  -226
  -243
  -261
  -279
  -298
  -318
  -338
  -360
  -382
  -405
  -429
  -453
  -479
  -506
  -534
  -563
  -593
Depreciation, amort., depletion, $m
  15
  11
  13
  16
  18
  21
  24
  28
  31
  35
  39
  42
  46
  51
  56
  61
  66
  71
  77
  83
  89
  95
  102
  109
  116
  123
  131
  139
  147
  156
  165
Funds from operations, $m
  50
  -60
  -65
  -71
  -77
  -84
  -92
  -100
  -109
  -118
  -127
  -137
  -148
  -159
  -170
  -182
  -195
  -208
  -221
  -235
  -249
  -264
  -280
  -296
  -313
  -330
  -348
  -367
  -386
  -406
  -428
Change in working capital, $m
  -6
  12
  14
  15
  17
  18
  20
  21
  23
  24
  26
  27
  28
  30
  31
  32
  34
  35
  36
  38
  39
  41
  42
  44
  46
  48
  50
  52
  54
  56
  59
Cash from operations, $m
  56
  -72
  -79
  -86
  -94
  -103
  -112
  -121
  -131
  -142
  -153
  -164
  -176
  -188
  -201
  -215
  -228
  -243
  -257
  -273
  -289
  -305
  -322
  -340
  -358
  -378
  -398
  -418
  -440
  -463
  -486
Maintenance CAPEX, $m
  0
  -8
  -10
  -12
  -15
  -17
  -20
  -23
  -27
  -30
  -34
  -38
  -42
  -46
  -51
  -56
  -61
  -66
  -71
  -77
  -83
  -89
  -95
  -102
  -109
  -116
  -123
  -131
  -139
  -147
  -156
New CAPEX, $m
  -56
  -19
  -21
  -24
  -26
  -28
  -31
  -33
  -35
  -38
  -40
  -42
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -59
  -61
  -63
  -66
  -68
  -71
  -74
  -77
  -80
  -84
  -87
  -91
Cash from investing activities, $m
  -56
  -27
  -31
  -36
  -41
  -45
  -51
  -56
  -62
  -68
  -74
  -80
  -86
  -92
  -99
  -106
  -113
  -120
  -127
  -136
  -144
  -152
  -161
  -170
  -180
  -190
  -200
  -211
  -223
  -234
  -247
Free cash flow, $m
  0
  -99
  -110
  -122
  -135
  -148
  -163
  -178
  -193
  -210
  -226
  -244
  -262
  -281
  -300
  -320
  -341
  -363
  -385
  -408
  -433
  -457
  -483
  -510
  -538
  -568
  -598
  -630
  -663
  -697
  -733
Issuance/(repayment) of debt, $m
  -2
  27
  30
  34
  37
  40
  44
  47
  50
  54
  57
  60
  63
  65
  68
  71
  74
  77
  80
  84
  87
  90
  94
  98
  101
  105
  110
  114
  119
  124
  129
Issuance/(repurchase) of shares, $m
  10
  107
  119
  132
  146
  160
  175
  191
  207
  224
  242
  259
  278
  298
  318
  339
  360
  383
  406
  430
  455
  481
  508
  536
  565
  595
  626
  659
  694
  729
  767
Cash from financing (excl. dividends), $m  
  8
  134
  149
  166
  183
  200
  219
  238
  257
  278
  299
  319
  341
  363
  386
  410
  434
  460
  486
  514
  542
  571
  602
  634
  666
  700
  736
  773
  813
  853
  896
Total cash flow (excl. dividends), $m
  8
  34
  39
  43
  48
  52
  56
  60
  64
  68
  72
  75
  79
  82
  86
  90
  93
  97
  101
  105
  109
  114
  118
  123
  128
  133
  138
  144
  150
  156
  163
Retained Cash Flow (-), $m
  -63
  -107
  -119
  -132
  -146
  -160
  -175
  -191
  -207
  -224
  -242
  -259
  -278
  -298
  -318
  -339
  -360
  -383
  -406
  -430
  -455
  -481
  -508
  -536
  -565
  -595
  -626
  -659
  -694
  -729
  -767
Prev. year cash balance distribution, $m
 
  124
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  52
  -80
  -88
  -98
  -108
  -119
  -131
  -143
  -156
  -170
  -184
  -200
  -215
  -232
  -249
  -267
  -286
  -305
  -325
  -346
  -367
  -390
  -413
  -437
  -462
  -488
  -515
  -544
  -573
  -604
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  50
  -73
  -77
  -81
  -84
  -86
  -88
  -89
  -90
  -89
  -88
  -85
  -82
  -78
  -73
  -68
  -62
  -56
  -50
  -44
  -38
  -32
  -27
  -22
  -18
  -14
  -11
  -8
  -6
  -5
Current shareholders' claim on cash, %
  100
  93.8
  88.4
  83.7
  79.6
  75.9
  72.6
  69.6
  66.9
  64.4
  62.1
  59.9
  57.9
  56.0
  54.2
  52.6
  51.0
  49.5
  48.1
  46.7
  45.4
  44.2
  43.0
  41.8
  40.7
  39.6
  38.6
  37.6
  36.7
  35.7
  34.8

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring; and DexCom G5 Mobile, a continuous glucose monitoring system. The company’s in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers; and sensor augmented insulin pumps. The company markets its products directly to endocrinologists, physicians, and diabetes educators. It has collaboration agreements with Animas Corporation and Tandem Diabetes Care, Inc. The company was founded in 1999 and is headquartered in San Diego, California.

FINANCIAL RATIOS  of  DexCom (DXCM)

Valuation Ratios
P/E Ratio -93.6
Price to Sales 10.8
Price to Book 21.8
Price to Tangible Book
Price to Cash Flow 110.4
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate 42.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 69.7%
Cap. Spend. - 3 Yr. Gr. Rate 47.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -19%
Ret/ On Assets - 3 Yr. Avg. -19.2%
Return On Total Capital -26%
Ret/ On T. Cap. - 3 Yr. Avg. -25.4%
Return On Equity -26.1%
Return On Equity - 3 Yr. Avg. -26%
Asset Turnover 1.6
Profitability Ratios
Gross Margin 66%
Gross Margin - 3 Yr. Avg. 67.7%
EBITDA Margin -8.7%
EBITDA Margin - 3 Yr. Avg. -8.6%
Operating Margin -11.2%
Oper. Margin - 3 Yr. Avg. -11.3%
Pre-Tax Margin -11.3%
Pre-Tax Margin - 3 Yr. Avg. -11.4%
Net Profit Margin -11.5%
Net Profit Margin - 3 Yr. Avg. -11.5%
Effective Tax Rate -1.5%
Eff/ Tax Rate - 3 Yr. Avg. -0.5%
Payout Ratio 0%

DXCM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DXCM stock intrinsic value calculation we used $573 million for the last fiscal year's total revenue generated by DexCom. The default revenue input number comes from 2016 income statement of DexCom. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DXCM stock valuation model: a) initial revenue growth rate of 22.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DXCM is calculated based on our internal credit rating of DexCom, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of DexCom.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DXCM stock the variable cost ratio is equal to 104%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $42 million in the base year in the intrinsic value calculation for DXCM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for DexCom.

Corporate tax rate of 27% is the nominal tax rate for DexCom. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DXCM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DXCM are equal to 14.6%.

Life of production assets of 10 years is the average useful life of capital assets used in DexCom operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DXCM is equal to 9.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $284 million for DexCom - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 83.344 million for DexCom is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of DexCom at the current share price and the inputted number of shares is $6.1 billion.

RELATED COMPANIES Price Int.Val. Rating
JNJ Johnson&Johnso 133.45 94.54  sell
ABT Abbott Laborat 48.88 423.88  str.buy
WST West Pharmaceu 85.28 62.37  sell
CAH Cardinal Healt 64.36 152.24  str.buy

COMPANY NEWS

▶ DexCom (DXCM) in Focus: Stock Moves 6.7% Higher   [Aug-03-17 08:44AM  Zacks]
▶ DexCom beats Street 2Q forecasts   [Aug-01-17 10:05PM  Associated Press]
▶ ETFs with exposure to DexCom, Inc. : July 24, 2017   [Jul-24-17 03:30PM  Capital Cube]
▶ ETFs with exposure to DexCom, Inc. : July 14, 2017   [Jul-14-17 02:03PM  Capital Cube]
▶ DexCom Announces Upcoming Conference Presentation   [Jul-07-17 08:00AM  Business Wire]
▶ DexCom, Inc. Value Analysis (NASDAQ:DXCM) : July 5, 2017   [Jul-05-17 01:28PM  Capital Cube]
▶ 3 Growth Stocks for Ambitious Investors   [Jun-09-17 01:27PM  Motley Fool]
▶ Company News for June 06, 2017   [Jun-06-17 10:04AM  Zacks]
▶ ETFs with exposure to DexCom, Inc. : May 29, 2017   [May-29-17 12:45PM  Capital Cube]
▶ ETFs with exposure to DexCom, Inc. : May 18, 2017   [May-18-17 01:40PM  Capital Cube]
▶ Will Wearable Technology Make Us Healthier?   [May-16-17 09:03AM  Motley Fool]
▶ ETFs with exposure to DexCom, Inc. : May 5, 2017   [May-05-17 04:05PM  Capital Cube]
▶ DexCom, Inc. Value Analysis (NASDAQ:DXCM) : May 3, 2017   [May-03-17 04:41PM  Capital Cube]
▶ Here's Why DexCom Stock Is Tanking Today   [12:40PM  Motley Fool]
▶ DexCom reports 1Q loss   [May-02-17 05:12PM  Associated Press]
▶ Sohn Investment Conference: Investing for good   [Apr-24-17 12:47PM  CNBC Videos]
▶ Dexcom adding 500 jobs in Mesa   [Apr-14-17 02:30PM  American City Business Journals]
▶ 3 Hot Stocks to Buy in April   [Apr-04-17 08:48AM  Motley Fool]
▶ 3 Top Diabetes Care Stocks to Buy in 2017   [Mar-17-17 08:06AM  Motley Fool]
▶ 3 Top Diabetes Care Stocks to Buy in 2017   [08:06AM  at Motley Fool]
▶ Better Buy: MannKind Corp. vs. Dexcom   [Mar-09-17 10:06AM  at Motley Fool]
▶ Billionaire George Soros Bought These 2 Biotech Stocks   [Mar-02-17 09:50AM  at Motley Fool]
▶ DexCom Announces Upcoming Conference Presentations   [Feb-22-17 04:01PM  Business Wire]
▶ 3 of the Highest-Growth Stocks in the Market Today   [Feb-06-17 08:31AM  at Motley Fool]
Stock chart of DXCM Financial statements of DXCM
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.